vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and NOODLES & Co (NDLS). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $122.1M, roughly 1.4× NOODLES & Co). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -4.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -1.2%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Noodles & Company is an American fast-casual restaurant that offers international and American noodle dishes in addition to soups and salads. Noodles & Company was founded in 1995 by Aaron Kennedy and is headquartered in Broomfield, Colorado. The company went public in 2013 and recorded a $457 million revenue in 2017. In mid-2022, there were 458 Noodles & Company locations across 31 states.
ESPR vs NDLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $122.1M |
| Net Profit | — | $-9.2M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | -5.2% |
| Net Margin | — | -7.5% |
| Revenue YoY | 143.7% | -4.1% |
| Net Profit YoY | — | 32.8% |
| EPS (diluted) | $0.32 | $-0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | — | ||
| Q3 25 | $87.3M | $122.1M | ||
| Q2 25 | $82.4M | $123.8M | ||
| Q1 25 | $65.0M | — | ||
| Q4 24 | $69.1M | $122.8M | ||
| Q3 24 | $51.6M | $127.4M | ||
| Q2 24 | $73.8M | $121.4M | ||
| Q1 24 | $137.7M | $124.3M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $-9.2M | ||
| Q2 25 | $-12.7M | $-9.1M | ||
| Q1 25 | $-40.5M | — | ||
| Q4 24 | — | $-6.8M | ||
| Q3 24 | $-29.5M | $-13.6M | ||
| Q2 24 | $-61.9M | $-6.1M | ||
| Q1 24 | $61.0M | $-6.1M |
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | -5.2% | ||
| Q2 25 | 8.6% | -5.2% | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | -6.4% | -3.9% | ||
| Q3 24 | -31.0% | -9.0% | ||
| Q2 24 | 3.5% | -3.4% | ||
| Q1 24 | 52.5% | -3.7% |
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | -7.5% | ||
| Q2 25 | -15.4% | -7.3% | ||
| Q1 25 | -62.2% | — | ||
| Q4 24 | — | -5.5% | ||
| Q3 24 | -57.2% | -10.7% | ||
| Q2 24 | -83.9% | -5.1% | ||
| Q1 24 | 44.3% | -4.9% |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | $-0.20 | ||
| Q2 25 | $-0.06 | $-0.20 | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | $-0.15 | ||
| Q3 24 | $-0.15 | $-0.30 | ||
| Q2 24 | $-0.33 | $-0.14 | ||
| Q1 24 | $0.34 | $-1.64 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $4.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $-38.9M |
| Total Assets | $465.9M | $280.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | $4.7M | ||
| Q2 25 | $86.1M | $1.4M | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | $3.3M | ||
| Q3 24 | $144.7M | $1.8M | ||
| Q2 24 | $189.3M | $1.3M | ||
| Q1 24 | $226.6M | $3.0M |
| Q4 25 | $-302.0M | — | ||
| Q3 25 | $-451.4M | $-38.9M | ||
| Q2 25 | $-433.5M | $-13.9M | ||
| Q1 25 | $-426.2M | — | ||
| Q4 24 | $-388.7M | $3.7M | ||
| Q3 24 | $-370.2M | $9.6M | ||
| Q2 24 | $-344.2M | $21.9M | ||
| Q1 24 | $-294.3M | $27.2M |
| Q4 25 | $465.9M | — | ||
| Q3 25 | $364.0M | $280.6M | ||
| Q2 25 | $347.1M | $319.4M | ||
| Q1 25 | $324.0M | — | ||
| Q4 24 | $343.8M | $340.5M | ||
| Q3 24 | $314.1M | $346.3M | ||
| Q2 24 | $352.3M | $360.4M | ||
| Q1 24 | $373.1M | $368.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $4.3M |
| Free Cash FlowOCF − Capex | — | $-2.8M |
| FCF MarginFCF / Revenue | — | -2.3% |
| Capex IntensityCapex / Revenue | 0.0% | 5.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-7.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | — | ||
| Q3 25 | $-4.3M | $4.3M | ||
| Q2 25 | $-31.4M | $4.0M | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $-35.0M | $5.8M | ||
| Q3 24 | $-35.3M | $4.7M | ||
| Q2 24 | $-7.2M | $7.0M | ||
| Q1 24 | $53.8M | $164.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | — | $1.1M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | $-35.5M | $-4.5M | ||
| Q2 24 | $-7.3M | $-1.6M | ||
| Q1 24 | $53.8M | $-15.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | -2.3% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -1.1% | ||
| Q3 24 | -68.7% | -3.5% | ||
| Q2 24 | -9.9% | -1.4% | ||
| Q1 24 | 39.0% | -12.2% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 5.8% | ||
| Q2 25 | 0.0% | 2.4% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 5.8% | ||
| Q3 24 | 0.3% | 7.2% | ||
| Q2 24 | 0.1% | 7.1% | ||
| Q1 24 | 0.1% | 12.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
NDLS
| Food And Beverage | $119.6M | 98% |
| Franchise | $2.5M | 2% |
